Yuya Sasaki

Yuya Sasaki

Auto-generated profile, based on publicly available information

Yuya Sasaki

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2016 in Blood
Verified
Journal Article
Open access
PDF file
HMHiroaki Miyoshi
Hiroaki Miyoshi
JKJunichi Kiyasu
Junichi Kiyasu
TKTakeharu Kato
Takeharu Kato
NYNoriaki Yoshida
Noriaki Yoshida
JSJoji Shimono
Joji Shimono
KOKoichi Ohshima
Koichi Ohshima
Key Points: PD-L1 expression in neoplastic cells or stromal cells is associated with poor or good prognosis in ATLL, respectively. Distinction of expression pattern of PD-L1 might be important on the point of prognostic and therapeutic markers in ATLL.

1 July 2019 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
DKDaisuke Kurita
Daisuke Kurita
HMHiroaki Miyoshi
Hiroaki Miyoshi
AIAyako Ichikawa
Ayako Ichikawa
KKKoji Kato
Koji Kato
YIYoshitaka Imaizumi
Yoshitaka Imaizumi
KOKoichi Ohshima
Koichi Ohshima
Methotrexate (MTX) carries a risk of lymphoproliferative disorders (LPDs), but MTX-associated LPDs (MTX-LPDs) can resolve spontaneously after MTX withdrawal. However, the precise clinicopathologic features of MTX-LPD remain unclear. We aimed to investigate the clinicopathologic characteristics, outcomes, and prognostic factors for histologic types of MTX-LPD. Paraffin-embedded tissue samples of 219 patients with MTX-LPD were analyzed. In total, 30,33,106, and 26 had reactive lymphoid hyperplasia (RH), polymorphic-LPD (Poly-LPD), diffuse large B-cell lymphomas (DLBCLs), and classic Hodgkin lymphoma (CHL), respectively. The clinicopathologic features of RH, Poly-LPD, DLBCLs, and CHL were as follows: extranodal involvement: 13.8% (4/29), 36.4% (12/33), 69.5% (73/105), and 15.4% (4/26); Epstein-Barr virus encoded RNA positivity: 55.2% (16/29), 71.9% (23/32), 45.3% (48/106), and 76.9% (20/26); necrosis: 0% (0/29), 51.5% (17/33), 34.3% (36/105), and 12.0% (3/25); and Hodgkin Reed-Sternberg-like cells: 17.2% (5/29), 50% (14/28), and 19.8% (21/106). The median duration from MTX withdrawal to the time of disease regression was 10.4, 3.0, 4.2, and 2.7 months for RH, Poly-LPD, DLBCLs, and CHL. After MTX withdrawal, progression-free survival was the greatest for RH, followed by for Poly-LPD, DLBCL, and CHL (all P<0.05). Overall survival did not differ significantly between the groups. On univariate analysis, the predictive factors for progression-free survival included plasma cell infiltrate for CHL, eosinophil infiltrate, age above 70 years, and extensive necrosis for Poly-LPD, while they were Epstein-Barr virus encoded RNA positivity and International Prognostic Index risk for DLBCL on multivariate analysis. In conclusion, histologic categorization and histology-specific factors could be useful for predicting MTX-LPD progression after MTX withdrawal.

14 December 2017 in Haematologica
Verified
Journal Article
Open access
PDF file
KKKeisuke Kawamoto
Keisuke Kawamoto
HMHiroaki Miyoshi
Hiroaki Miyoshi
TSTakaharu Suzuki
Takaharu Suzuki
YKYasuji Kozai
Yasuji Kozai
KKKoji Kato
Koji Kato
KOKoichi Ohshima
Koichi Ohshima
The characteristics of adult patients with chronic active Epstein-Barr virus infection are poorly recognized, hindering early diagnosis and an improved prognosis. We studied 54 patients with adult-onset chronic active Epstein-Barr virus infection diagnosed between 2005 and 2015. Adult onset was defined as an estimated age of onset of 15 years or older. To characterize the clinical features of these adults, we compared them to those of 75 pediatric cases (estimated age of onset <15 years). We compared the prognosis of adult-onset chronic active Epstein-Barr virus infection with that of patients with nasal-type (n=37) and non-nasal-type (n=45) extranodal NK/T-cell lymphoma. The median estimated age of onset of these lymphomas was 39 years (range, 16–86 years). Compared to patients with pediatric-onset disease, those in whom the chronic active Epstein-Barr virus infection developed in adulthood had a significantly decreased incidence of fever (P=0.005), but greater frequency of skin lesions (P<0.001). Moreover, hypersensitivity to mosquito bites and the occurrence of hydroa vacciniforme were less frequent in patients with adult-onset disease (P<0.001 and P=0.0238, respectively). Thrombocytopenia, high Epstein-Barr virus nuclear antigen antibody titer, and the presence of hemophagocytic syndrome were associated with a poor prognosis (P=0.0087, P=0.0236, and P=0.0149, respectively). Allogeneic hematopoietic stem cell transplantation may improve survival (P=0.0289). Compared to pediatric-onset chronic active Epstein-Barr virus infection and extranodal NK/T-cell lymphoma, adult-onset chronic active Epstein-Barr virus infection had a poorer prognosis (P<0.001 and P=0.0484, respectively). Chronic active Epstein-Barr virus infection can develop in a wide age range, with clinical differences between adult-onset and pediatric-onset disease. Adult-onset chronic active Epstein-Barr virus infection is a disease with a poor prognosis. Further research will be needed.

7 February 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
YSYuya Sasaki
Yuya Sasaki
HKHagop M. Kantarjian
Hagop M. Kantarjian
Nicholas J. ShortNicholas J. Short
Nicholas J. Short
FWFeng Wang
Feng Wang
KFKen Furudate
Ken Furudate
EJElias Jabbour
Elias Jabbour

11 March 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
MSMatthew Schwede
Matthew Schwede
KJKatharina Jahn
Katharina Jahn
JKJack Kuipers
Jack Kuipers
LMLinde A. Miles
Linde A. Miles
RBRobert L. Bowman
Robert L. Bowman
RMRavindra Majeti
Ravindra Majeti

19 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
JSJoji Shimono
Joji Shimono
HMHiroaki Miyoshi
Hiroaki Miyoshi
FAFumiko Arakawa
Fumiko Arakawa
KSKensaku Sato
Kensaku Sato
TFTakuya Furuta
Takuya Furuta
KOKoichi Ohshima
Koichi Ohshima
Prognostic factors for histiocytic and dendritic cell neoplasms Prognostic factors for histiocytic and dendritic cell neoplasms